Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer

Journal of the National Cancer Institute

Volumn 93, Issue 8, 2001, Pages 605-617

  Lippman, Scott M ^a   Lee, J Jack ^a   Karp, Daniel D ^b   Vokes, Everett E ^c   Benner, Steven E ^a   Goodman, Gary E ^d   Khuri, Fadlo R ^e   Marks, Randolph ^f   Winn, Rodger J ^a   Fry, Willard ^b   Graziano, Stephen L ^c   Gandara, David R ^d   Okawara, Gordon ^e   Woodhouse, Charles L ^f   Williams, Brendell ^a   Perez, Cherie ^a   Kim, Hyung W ^a   Lotan, Reuben ^a   Roth, Jack A ^a   Hong, Waun Ki ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Eastern Cooperative Oncology Group   (United States)

^c Cancer and Leukemia Group B   (United States)

^d Southwest Oncology Group   (United States)

^e RADIATION THERAPY ONCOLOGY GROUP   (United States)

^f North Central Cancer Treatment Group Rochester   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BETA CAROTENE; FENRETINIDE; GEMFIBROZIL; ISOTRETINOIN; PLACEBO; RETINOIC ACID; RETINOID; RETINOL; RETINOL PALMITATE; TRIACYLGLYCEROL;

ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHEILITIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRY SKIN; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPERTRIGLYCERIDEMIA; LIVER FUNCTION TEST; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SECOND CANCER; SIDE EFFECT; SKIN TOXICITY; SMOKING; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; STATISTICS; TIME; VISUAL IMPAIRMENT;

EID: 0035906224     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.8.605     Document Type: Article

References (113)

1. Cancer statistics 2001
2. Revisions in the International System for Staging Lung Cancer
3. Early lung cancer detection: Results of the initial (prevalence) radiologic and cytologic screening in the Memorial Sloan-Kettering study
4. Second primary lung carcinoma
5. Postsurgical stage I bronchogenic carcinoma: Morbid implications of recurrent disease
6. 0 non-small cell lung cancer
7. Not yet standard: Retinoids versus second primary tumors
8. Control of squamous differentiation in tracheobronchial and epidermal epithelial cells: Role of retinoids
9. Retinoids as preventive and therapeutic anticancer agents
10. Retinoids as preventive and therapeutic anticancer agents
11. Cancer chemoprevention
12. Retinoids, carotenoids and micronutrients
13. Tissue changes following deprivation of fat-soluble A vitamin
14. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids)
15. Retinoids and cancer in experimental animals
16. 13-cis-retinoic acid in the treatment of oral leukoplakia
17. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck
18. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis
19. Head and neck cancer
20. Adjuvant treatment of stage I lung cancer with high-dose vitamin A
21. Retinoid chemoprevention of upper aerodigestive tract carcinogenesis
22. Retinoid chemoprevention of aerodigestive cancer: From basic research to the clinic
23. Second malignant tumors in head and neck squamous cell carcinoma: The overshadowing threat for patients with early-stage disease
24. Prognostic factors for survival in patients with inoperable lung cancer
25. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification
26. Interim analyses in randomized clinical trials: Ramifications and guidelines for practitioners
27. A multiple testing procedure for clinical trials
28. Retinoids in cancer therapy
29. Clinical and laboratory adverse effects associated with long-term, low-dose isotretinoin: Incidence and risk factors
30. Effects of long-term intake of retinol on selected clinical and laboratory indexes
31. Effect of long-term beta-carotene and vitamin A on serum cholesterol and triglyceride levels among participants in the Carotene and Retinol Efficacy Trial (CARET)
32. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin
33. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: A double-blind, placebo-controlled study
34. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: A randomized, double-blind, controlled trial
35. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: A randomized trial
36. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma
37. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
38. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia
39. Use of retinoic acids in the treatment of peripheral T-cell lymphoma: A pilot study
40. All-trans-retinoic acid in acute promyelocytic leukemia
41. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
42. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists
43. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats
44. Transcription-modulating drugs: A new frontier in the treatment of essential hypertension
45. Retinoids: Versatile biological response modifiers of vascular smooth muscle phenotype
46. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer
47. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia
48. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)-retinamide in F9 embryonal carcinoma cells
49. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium
50. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers
51. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
52. Beta-Carotene: An unusual type of lipid antioxidant
53. Potent preventive action of alpha-carotene against carcinogenesis: Spontaneous liver carcinogenesis and promoting stage of lung and skin carcinogenesis in mice are suppressed more effectively by alpha-carotene than by beta-carotene
54. Beta carotene and its oxidation products have different effects on microsome mediated binding of benzo[a]pyrene to DNA
55. Oxidative DNA damage by vitamin A and its derivative via superoxide generation
56. Co-carcinogenic effect of beta-carotene
57. Retinoid signaling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke
58. Oxidative DNA damage by vitamin A and its derivative via superoxide generation
59. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin
60. Nuclear retinoid acid receptor beta in bronchial epithelium of smokers before and during chemoprevention
61. Placebo-controlled trial of 13-cis-retinoic acid activity on retinoic acid receptor-beta expression in a population at high risk: Implications for chemoprevention of lung cancer
62. Evidence of a retinoid signaling alteration involving the activator protein 1 complex in tumorigenic human bronchial epithelial cells and non-small cell lung cancer cells
63. Differential responses of normal, premalignant, and malignant human bronchial epithelial cells to receptor-selective retinoids
64. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells
65. Enhancement of Calu-1 human lung carcinoma cell growth in serum-free medium by retinoids: Dependence on AP-1 activation, but not on retinoid response element activation
66. The impact of smoking status and disease stage and site on secondary primary tumor incidence and primary tumor recurrence in the head and neck retinoid chemoprevention trial
67. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: Long-term follow-up
68. Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: Long-term follow-up
69. The effect of the synthetic retinoid etretinate on sputum cytology: Results from a randomised trial
70. Retinoid refractoriness occurs during lung carcinogenesis despite functional retinoid receptors
71. Topical delivery of 13-cis-retinoic acid by inhalation up-regulates expression of rodent lung but not liver retinoic acid receptors
72. Inhaled isotretinoin (13-cis retinoic acid) is an effective lung cancer chemopreventive agent in A/J mice at low doses: A pilot study
73. Human lung cancer cell lines exhibit resistance to retinoic acid treatment
74. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells
75. High frequency of retinoic acid receptor beta abnormalities in human lung cancer
76. A specific defect in the retinoic acid response associated with human lung cancer cell lines
77. Regulation of RAR beta expression by RAR- and RXR-selective retinoids in human lung cancer cell lines: Effect on growth inhibition and apoptosis induction
78. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: Implications for lung cancer development
79. Expression of retinoid receptor genes and proteins in non-small-cell lung cancer
80. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas
81. Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression
82. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer
83. Retinoic acid receptor and retinoid X receptor alterations in lung cancer precursor lesions
84. Unique anti-activator protein-1 activity of retinoic acid receptor beta
85. Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP-TF and their heterodimerization
86. Evidence for impaired retinoic acid receptor-thyroid hormone receptor AF-2 cofactor activity in human lung cancer
87. Co-activators and co-repressors in the integration of transcriptional responses
88. Effects of benzo[a]pyrene diol epoxide on expression of retinoic acid receptors in esophageal cancer cells
89. Loss of retinoic acid receptor-beta expression is an early event during esophageal carcinogenesis
90. Expression and up-regulation of retinoic acid receptor-beta is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines
91. -/-) exhibit liver retinoid accumulation and reduced retinoic acid metabolism
92. Tobacco smoke carcinogens and lung cancer
93. Induction of gastrin releasing peptide by all-trans retinoic acid in small cell lung cancer cells
94. Expression of mRNA for gastrin-releasing peptide receptor by human bronchial epithelial cells. Association with prolonged tobacco exposure and responsiveness to Bombesin-like peptides
95. All-trans-retinoic acid upregulates TNF receptors and potentiates TNF-induced activation of nuclear factors-kappaB, activated protein-1 and apoptosis in human lung cancer cells
96. Benzo[a]pyrene activates the human p53 gene through induction of nuclear factor kappaB activity
97. Phase-III intergroup trial of 13-cis-retinoic acid to prevent second primary tumors in stage-I non-small cell lung cancer (NSCLC): Interim report of NCI # 191-0001
98. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma
99. Cancer chemoprevention: Progress and promise
100. Tamoxifen prevention of breast cancer: An instance of the fingerpost
101. Primary cancer prevention trials
102. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
103. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
104. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
105. Recent advances in chemoprevention of cancer
106. Frequent microsatellite alterations at chromosome 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment
107. Clonal genetic alterations in the lungs of current and former smokers
108. Predicting cancer development in oral leukoplakia: Ten years of translational research
109. 15-LOX-1: A novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells
110. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells
111. Combinatorial chemoprevention of intestinal neoplasia
112. st century: Genetics, risk modeling, and molecular targets